188 related articles for article (PubMed ID: 29334040)
1. Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease.
Bruno V; Freitas ME; Mancini D; Lui JP; Miyasaki J; Fox SH
Can J Neurol Sci; 2018 Jan; 45(1):23-29. PubMed ID: 29334040
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke.
Bakheit AM; Pittock S; Moore AP; Wurker M; Otto S; Erbguth F; Coxon L
Eur J Neurol; 2001 Nov; 8(6):559-65. PubMed ID: 11784339
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study.
Wissel J; Kanovsky P; Ruzicka E; Bares M; Hortova H; Streitova H; Jech R; Roth J; Brenneis C; Müller J; Schnider P; Auff E; Richardson A; Poewe W
J Neurol; 2001 Dec; 248(12):1073-8. PubMed ID: 12013585
[TBL] [Abstract][Full Text] [Related]
4. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.
Ondo WG; Hunter C; Moore W
Neurology; 2004 Jan; 62(1):37-40. PubMed ID: 14718694
[TBL] [Abstract][Full Text] [Related]
5. The analgesic effect of botulinum-toxin A on postwhiplash neck pain.
Braker C; Yariv S; Adler R; Badarny S; Eisenberg E
Clin J Pain; 2008 Jan; 24(1):5-10. PubMed ID: 18180629
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study.
Tassorelli C; De Icco R; Alfonsi E; Bartolo M; Serrao M; Avenali M; De Paoli I; Conte C; Pozzi NG; Bramanti P; Nappi G; Sandrini G
Parkinsonism Relat Disord; 2014 Nov; 20(11):1140-4. PubMed ID: 25175601
[TBL] [Abstract][Full Text] [Related]
7. Combined botulinum toxin type A with modified constraint-induced movement therapy for chronic stroke patients with upper extremity spasticity: a randomized controlled study.
Sun SF; Hsu CW; Sun HP; Hwang CW; Yang CL; Wang JL
Neurorehabil Neural Repair; 2010 Jan; 24(1):34-41. PubMed ID: 19729582
[TBL] [Abstract][Full Text] [Related]
8. Can botulinum toxin decrease carer burden in long term care residents with upper limb spasticity? A randomized controlled study.
Lam K; Lau KK; So KK; Tam CK; Wu YM; Cheung G; Liang KS; Yeung KM; Lam KY; Yui S; Leung C
J Am Med Dir Assoc; 2012 Jun; 13(5):477-84. PubMed ID: 22521630
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
10. Treatment of pain attributed to plantar fasciitis with botulinum toxin a: a short-term, randomized, placebo-controlled, double-blind study.
Babcock MS; Foster L; Pasquina P; Jabbari B
Am J Phys Med Rehabil; 2005 Sep; 84(9):649-54. PubMed ID: 16141740
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
Chinnapongse R; Gullo K; Nemeth P; Zhang Y; Griggs L
Mov Disord; 2012 Feb; 27(2):219-26. PubMed ID: 21887710
[TBL] [Abstract][Full Text] [Related]
12. Does botulinum toxin type A decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity?: a randomized, double-blind, placebo-controlled trial.
Marciniak CM; Harvey RL; Gagnon CM; Duraski SA; Denby FA; McCarty S; Bravi LA; Polo KM; Fierstein KM
Am J Phys Med Rehabil; 2012 Dec; 91(12):1007-19. PubMed ID: 23064478
[TBL] [Abstract][Full Text] [Related]
13. Effects of botulinum toxin A in ambulant adults with spastic cerebral palsy: a randomized double-blind placebo controlled-trial.
Maanum G; Jahnsen R; Stanghelle JK; Sandvik L; Keller A
J Rehabil Med; 2011 Mar; 43(4):338-47. PubMed ID: 21305227
[TBL] [Abstract][Full Text] [Related]
14. Management of spasticity associated pain with botulinum toxin A.
Wissel J; Müller J; Dressnandt J; Heinen F; Naumann M; Topka H; Poewe W
J Pain Symptom Manage; 2000 Jul; 20(1):44-9. PubMed ID: 10946168
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of therapeutic benefits of botulinum toxin for foot dystonia associated with Parkinson's disease.
Ni P; Xu YY; Wang LN; Cao JQ; Luo WF; Zhang QL; Li X; Zhou XP; Liu J
Toxicon; 2024 Feb; 238():107587. PubMed ID: 38142904
[TBL] [Abstract][Full Text] [Related]
16. Incobotulinum toxin A in Parkinson's disease with foot dystonia: A double blind randomized trial.
Rieu I; Degos B; Castelnovo G; Vial C; Durand E; Pereira B; Simonetta-Moreau M; Sangla S; Fluchère F; Guehl D; Burbaud P; Geny C; Gayraud D; Ory-Magne F; Bouhour F; Llinares E; Derost P; Marques A; Durif F
Parkinsonism Relat Disord; 2018 Jan; 46():9-15. PubMed ID: 29102441
[TBL] [Abstract][Full Text] [Related]
17. Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A.
Yelnik AP; Colle FM; Bonan IV; Vicaut E
J Neurol Neurosurg Psychiatry; 2007 Aug; 78(8):845-8. PubMed ID: 17088333
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Intralesional Botulinum Toxin A for Treatment of Painful Cutaneous Leiomyomas: A Randomized Clinical Trial.
Naik HB; Steinberg SM; Middelton LA; Hewitt SM; Zuo RC; Linehan WM; Kong HH; Cowen EW
JAMA Dermatol; 2015 Oct; 151(10):1096-102. PubMed ID: 26244563
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Single Botulinum Toxin Type A (Botox®) Injection for Relief of Upper Trapezius Myofascial Trigger Point: A Randomized, Double-Blind, Placebo-Controlled Study.
Kwanchuay P; Petchnumsin T; Yiemsiri P; Pasuk N; Srikanok W; Hathaiareerug C
J Med Assoc Thai; 2015 Dec; 98(12):1231-6. PubMed ID: 27004309
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin for myofascial pain syndromes in adults.
Soares A; Andriolo RB; Atallah AN; da Silva EM
Cochrane Database Syst Rev; 2012 Apr; (4):CD007533. PubMed ID: 22513950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
